Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 99 | ECE2024

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

Card image cap
We are pleased to announce that ECE 2024 will be held in Stockholm, Sweden from 11-14 May 2024. We will, once again, be offering the hybrid format next year so you can join us in person in Sweden or remotely with ECE@Home.

Oral Communications

Oral Communications 13: Late Breaking

ea0099oc13.1 | Oral Communications 13: Late Breaking | ECE2024

BCL2 expression is enriched in androgen receptor-negative advanced prostate cancer:

Jimenez-Vacas Juan M , Westaby Daniel , Figueiredo Ines , Rekowski Jan , Pettinger Claire , Gurel Bora , Bogdan Denisa , Buroni Lorenzo , Neeb Antje , Padilha Ana , Taylor Joe , Zeng Wanting , Das Souvik , Hobern Emily , Riisnaes Ruth , Crespo Mateus , Miranda Susana , Ferreira Ana , Hanratty Brian , Nava Rodrigues Daniel , Bertan Claudia , Seed George , Fenor de La Maza Maria de Los Dolores , Guo Christina , Carmichael Juliet , Grochot Rafael , Chandran Khobe , Stavridi Anastasia , Varkaris Andreas , Stylianou Nataly , Hollier Brett , Tunariu Nina , Balk Steven , Carreira Suzanne , Yuan Wei , Nelson Peter , Corey Eva , Haffner Michael , de Bono Johann , Sharp Adam

Background: Treatment resistance in prostate cancer can be the result of multiple different tumour cell adaptations generating castration-resistant prostate cancer (CRPC). Despite advancements in treatment, CRPC remains a highly lethal disease. Some CRPCs become AR independent with loss of AR expression and lineage plasticity, urgently requiring novel therapeutic strategies. BCL2 can be upregulated in some CRPCs and may be a therapeutic target for this disease subset.<p cl...

ea0099oc13.2 | Oral Communications 13: Late Breaking | ECE2024

Assessment of mitochondrial peptide humanin in women with polycystic ovary syndrome: Serum and skeletal muscle profile

Sonmezoglu Kutuk Irem , Akı Senay , Demirel Ali Haydar , Mumusoglu Sezcan , Ciftci Turkmen Turan , Yildiz Bulent

Background and Aim: Humanin is a mitochondria-derived peptide (MDP) secreted in response to oxidative stress and linked to diverse cellular processes including inflammation and insulin resistance. Humanin has been shown to be downregulated in polycystic ovaries and exogenous humanin supplementation has attenuated insulin resistance and ovarian morphological abnormalities in a PCOS rat model. The aim of this study was to investigate the role of humanin in the pathophysiology of...

ea0099oc13.3 | Oral Communications 13: Late Breaking | ECE2024

Circulating CircRNAs for early diagnosis and prediction of gdm and their impact on trophoblast cell function

Ma Shuo , Wu Guoqiu

Background: Gestational diabetes mellitus (GDM) is one of the most common complications during pregnancy, with a globally increasing incidence that significantly affects maternal and infant health. Currently, there is a lack of effective early diagnostic markers for GDM. Therefore, it is necessary to identify diagnostic biomarkers for early screening of GDM during pregnancy. Circular RNA (CircRNA) has been found to be a structurally unique non-coding RNA, more stable than line...

ea0099oc13.4 | Oral Communications 13: Late Breaking | ECE2024

Protective effect of growth hormone-releasing hormone (GHRH) and its agonistic analog MR-409 in Alzheimer’s disease

Pedrolli Francesca , Morello Giulia , Gesmundo Iacopo , Cai Renzhi , Sha Wei , Schally Andrew V. , Ghigo Ezio , Tamagno Elena , Guglielmotto Michela , Granata Riccarda

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the formation of amyloid-β (Aβ) plaques and Tau neurofibrillary tangles, leading to neuronal loss, inflammation, reduced neurogenesis, and cognitive impairment. Currently, there is no effective cure for AD, highlighting the urgent need for novel therapeutic strategies. Growth hormone-releasing hormone (GHRH), besides promoting the release of pituitary growth hormone (GH), exerts many perip...

ea0099oc13.5 | Oral Communications 13: Late Breaking | ECE2024

Use of thiazide diuretics in hypoparathyroidism: indication and effects

Schernthaner-Reiter Marie Helene , Looser Claudius , Nagel Anna , Kautzky-Willer Alexandra , Luger Anton , Vila Greisa

Introduction: Hypoparathyroidism can occur post-surgically after thyroid or parathyroid surgery or in autoimmune or genetic diseases. Over several decades, the management of hypoparathyroidism included only supplementation with calcium, vitamin D3 (cholecaliferol), as well as active 1,25-dihydroxyvitamin D (calcitriol). In cases with severe hypoparathyroidism, this treatment can be limited by hypercalciuria, and these patients often need substitution with recombinant parathyro...

ea0099oc13.6 | Oral Communications 13: Late Breaking | ECE2024

Growth hormone-releasing hormone (GHRH) promotes transdifferentiation of myoblasts and white adipocytes into brown/beige adipocytes

Bertoldo Alessia , Granato Giuseppina , Gesmundo Iacopo , Ghigo Ezio , Granata Riccarda

Brown adipocytes dissipate energy through the production of heat, acting as a defense against cold and obesity, and secrete batokines, that positively regulate metabolic functions. Thus, identifying brown-promoting molecules is crucial for developing novel therapeutic strategies against obesity and metabolic disorders. Of note, differentiation into myoblasts and later myocytes of myogenic factor 5 (Myf5) positive progenitors, the same from which brown adipocytes originate, is ...